Emerging treatments for ovarian cancer

Bibliography

• EDMONDSON RJ, MONAGHAN JM: The epidemiology of ovarian cancer. Int. Cynecol. Cancer (2001) 11:423–429.
   PubMed Web of Science ®Google Scholar
• STRUEWING JP, HARTGE P, WACHOLDER S et al.: The risk of cancer associated with specific mutations of BRCA1 and 2 among Ashkenazi Jews. N Engl. Med (1997) 336:1401–1408.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: NIH Consensus Development Panel on Ovarian Cancer. JA/VIA (1995) 273:491–497.
   Web of Science ®Google Scholar
• LIOTTA L: Proteomics: the next revolutionin molecular medicine. Chemotherapy Foundation Symposium, New York, USA (2002) (Presentation).
   Google Scholar
• NO AUTHORS LISTED: American Cancer Society: cancer facts and figures 2001. American Cancer Society, Atlanta, USA (2001).
   Google Scholar
• MUDERSPACH L, MUGGIA FM, CONTI PS: Second-look for stage III epithelial ovarian cancer: rationale and current issues. Cancer Treat. Rev (1996) 21(6):499–511.
   PubMed Web of Science ®Google Scholar
• OZOLS R et al.: Carboplatin and paclitaxel versus cisplatin and paclitaxel in ovarian cancer. Proc. Am. Soc. Clin. Oncol (1999) 18:A1374.
   Google Scholar
• MCGUIRE WP, HOSKINS WJ, BRADY MF et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl. J. Med. (1996) 334:1–6.
   PubMed Web of Science ®Google Scholar
• PICCART MJ, BERTELSEN K, JAMES K et al.: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. Nati Cancer Inst. (2000) 92:699–708.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, BRALY PS, BRADY MF et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. .1. Clin. Oncol. (2000) 18:106–115.
   Web of Science ®Google Scholar
• NO AUTHORS LISTED: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. International Collaborative Ovarian Neoplasm (ICON) Collaborators. Lancet (2002) 360:505–515.
   PubMed Web of Science ®Google Scholar
• DU BOIS A, LUCK HJ, BAUKNECHT T et al.: First-fine chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a Phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. Clin. Omni (1999) 17(1):46–51.
   PubMed Web of Science ®Google Scholar
• VASEY PA, ATKINSON R, COLEMAN R et al.: Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br. Cancer (2001) 84(2):170–178.
   Google Scholar
• GORDON AN, FLEAGLE JT, GUTHRIE D et al: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. Clin. Oncol (2001) 19:3312–3322.
   Web of Science ®Google Scholar
• MUGGIA FM, HAINSWORTH JD, JEFFERS S et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Clin. Oncol (1997) 15(3):987–993.
   Web of Science ®Google Scholar
• MISSET J-L, VENNIN P, CHOLLET P et al.: Multicenter Phase II-III study of oxaliplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann. Oncol (2001) 12:1411–1415.
   PubMed Web of Science ®Google Scholar
• GARCIA A, MUGGIA FM: Activity of anthracyclines in refractory ovarian cancer: recent experience and review. Cancer Invest. (1997) 15:329–334.
   PubMed Web of Science ®Google Scholar
• ROSE PG, BLESSING JA, MAYER AR et al.: Prolonged oral etoposide as second-line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a GOG study. I Clin. Oncol (1998) 16:405–410.
   Web of Science ®Google Scholar
• BURGER RA, DISAIA PJ, ROBERTS JA et al.: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Cynecol Oncol (1999) 72:148–153.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING J, BALL H et al.: Phase II trial of paclitaxel in patients with progressive ovarian cancer after platinum-based chemotherapy: a GOG study. J. Clin. Oncol (1994) 12:1748–1753.
   PubMed Web of Science ®Google Scholar
• KAVANAGH JJ, KUDELKA AP, DE LEON CG et al.: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. (1996) 2:837–842.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, MILLWARD MJ, BELL D et al.: A Phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol (1998) 9:1343–1345.
   PubMed Web of Science ®Google Scholar
• WASSERMAN T, CARTER SK: Tabular analysis of anticancer drug activity. Cancer Chemother. (1975) 6(3):399–419.
   Google Scholar
• BOOKMAN MA, MALMSTROM H, BOLIS G et al.: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Clin. Oncol (1998) 16:3345–3352.
   Web of Science ®Google Scholar
• EISENHAUER EA, VERMORKEN JB, VAN GLABBEKE M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Omni (1997) 8(10):963–968.
   Google Scholar
• KEHRER DF, BOS AM, VERWEIJ J et al.: Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. Clin. Omni (2002) 20(5):1222–1231.
   PubMed Web of Science ®Google Scholar
• VERSCHRAEGEN CE GUPTA E, LOYER E et al.: A Phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory ovarian, tubal or peritoneal cancer. Anticancer Drugs (1999) 10(4):375–383.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, HAKES T, REICHMAN B et al.: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. (1992) Clin. Omni 10:243–248.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, BLESSING JA, MOORED et al: Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian carcinoma: a GOG Phase II trial. Clin. Omni (1998) 69:226–229.
   Google Scholar
• PECORELLI S: EORTC trial chair. (unpublished).
   Google Scholar
• ALBERTS DS, GARCIA DJ, FISHER E, LIU PY: Southwest Oncology Group experience with intraperitoneal chemotherapy of ovarian cancer. In: Current clinical oncology: regional chemotherapy Markman M (Ed.), Humana Press Inc, Totowa, NJ, USA (2000):179–191.
   Google Scholar
• MUGGIA FM, LIU PY, ALBERTS DS et al.: Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy. Cynecol Oncol (1996) 61:395–402.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, JEFFERS S, MUDERSPACH L et al.: Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Cynecol Oncol (1997) 66:185–191.
   Google Scholar
• LU J, LIEBES L, HOCHSTER H et al: Phase I and pharmacologic study of intraperitoneal topotecan and cisplatin. PrOC. Am. Assoc. Cancer Res. (2003) (Abstract).
   Google Scholar
• BARAKAT RC, SPRIGGS DR: Memorial Sloan-Kettering Cancer Center experience with intraperitoneal chemotherapy of ovarian cancer. In: Current clinical oncology: regional chemotherapy Markman M, Humana Press Inc, Totowa, NJ, USA (2000):167–177.
   Google Scholar
• ROTHENBERG M, LIU PY, WILCZYNSKI S et al: Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Cynecol Oncol (2001) 82:317–322.
   PubMed Web of Science ®Google Scholar
• •Review of consolidation as a concept following initial induction.
   Google Scholar
• SANTOSO JT, TANG DC, LANE SB et al.: Adenovirus-based p53 gene therapy in ovarian cancer. Cynecol Oncol (1995) 59:171–178.
   PubMed Web of Science ®Google Scholar
• EPENETOS AA, HIRD V, LAMBERT H et al.: Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. Cynecol Oncol (2000) 10(S1):44–46.
   PubMed Web of Science ®Google Scholar
• EHLEN T, NICODEMUS CE NOUJAIM AA et al.: Induction of tumor protective immunity utilizing the CA125 specific monoclonal OvaRex MAb-B43.13 in a cohort of patients with advanced recurrent ovarian cancer. Cynecol Oncol (2001) 80:310.
   Google Scholar
• SCHULTES BC, NICODEMUS CE BEREK JS et al.: Use of OvaRex® MAb-643.13 as an immunotherapeutic treatment of epithelial ovarian cancer: experience as single agent post first-line therapy in combination with chemotherapy in recurrent disease. Ear: Cancer (2002) 38 (Suppl. 7):S137 (Abstract #455).
   Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: biologic activities and clinical implications. J. Clio. Oncol (2000) 18:1135–1149.
   PubMed Web of Science ®Google Scholar
• LENGYEL E, SCHMALFELDT B, KONIK E et al.: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Cynecol. Oncol (2001) 82:291–298.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM: Search for the optimal treatment of ovarian cancer: heavy metals, 'belly baths' and ...yew trees.' Clio. Oncol. (1992) 10:683–685.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM: Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin. Oncol (1989) 16\(Suppl. 5):1–7.
   Google Scholar
• PICCART MJ, GREEN JA, LACAVE AJ et al.: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized Phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J. Clio. Oncol. (2000) 18:1193–2002.
   PubMed Web of Science ®Google Scholar
• •A clinical trial positioning oxaliplatin as a valuable second-line agent for patients with potentially still platinum-sensitive ovarian cancer.
   Google Scholar
• VERSCHRAEGGEN C. MANSFIELD P, FEIG B et al.: Phase I study of an intraperitoneal liposomal cisplatin analog L-NDDP for treatment of peritoneal carcinomatosis. Proc. Am. Soc. Clio. °pea (1999) 18:364a (Abstract #1405).
   Google Scholar
• AKAZA H, TOGASHI M, NISHIO Y et al.: Phase II study of cisdiammine(glycolato) platinum, 265-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother. Pharmacol. (1992) 31:187–192.
   PubMed Web of Science ®Google Scholar
• GIETEMA JA, DE VRIES EGE, SLEIJFER DT et al.: A Phase I study of 1,2-diammineomethyl-cyclobutane-platinum (II)-lactate (D-19466, lobaplatin) administered daily for 5 days. Br. J. Cancer (1993) 67:396–401.
   PubMed Web of Science ®Google Scholar
• GIETEMA JA, VELDUIS GJ, GUCHELAAR HJ et al.: Phase II and pharmacokinetic study of lobaplatin with relapsed ovarian cancer. Br. J. Cancer (1995) 71:1302–1305.
   PubMed Web of Science ®Google Scholar
• MCKEAGE MJ, RAYNAUD F, WARD J et al.: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J. Clio. °pea (1997) 15:2691–2700.
   Web of Science ®Google Scholar
• MANZOTTI C, PRATESI G, MENTA E et al.: BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clio. Cancer Res. (2000) 6(7):2626–2634.
   PubMed Web of Science ®Google Scholar
• RAYNAUD Fl, BOXALL FE, GODDARD PL et al: Cis-amminedichloro (2-methylpyrimidine) platinum (II) (AMD473, a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clio. Cancer Res. (1997) 3:2063–2074.
   PubMed Web of Science ®Google Scholar
• NEWMAN MS, COLBERN GT, WORKING PK et al.: Comparative pharmacokinetics, tissue distribution and therapeutic effectiveness of cisplatin encapsulated in long-circulating pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol (1999) 43:1–7.
   PubMed Web of Science ®Google Scholar
• •Example of predinical activity in xenografts that did not breed true in the clinic.
   Google Scholar
• MUGGIA FM, VOGELZANG N, SCHNIPPER E: Phase I and Phase II clinical studies of SPI-77 (in preparation).
   Google Scholar
• PICCART MJ, GORE M, TEN BOKKEL HUININK W et al.: Docetaxel: an active new drug for treatment of epithelial ovarian cancer. Natl. Cancer lost (1995) 87:676–681.
   PubMed Web of Science ®Google Scholar
• LI C, YU DF, NEWMAN RA et al.: Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res. (1998) 58:2404–2409.
   PubMed Web of Science ®Google Scholar
• SABBATINI P, BROWN J, PETERS WA et al: Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer. Eur. J. Cancer (2002) 38 (Suppl. 7):S130 (Abstract #430).
   Google Scholar
• TARABOLETTI G, MICHELETTI G, RIEPPI M et al.: Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clio. Cancer Res. (2002) 8(4):1182–1188.
   PubMed Web of Science ®Google Scholar
• ••Predinical study that separates the anti-angiogenic from the anti-proliferative effects of taxanes.
   Google Scholar
• BERNACKI R, VREDENBURG M, KANER P et al: IDN-5390, an orally active, antiangiogenic taxoid with low toxicity, ideally suited for metronomic dosing. Eur. Cancer(2002) 38 (Suppl. 7):S37-S38 (Abstract #109).
   Google Scholar
• BEERAM M, HIDALGO M, RODRIGUEZ G et al: A Phase land pharmacokinetic (PK) study of the novel taxane BMS 184476 administered as a 1- hour intravenous (IV) infusion weekly.Proc. Am. Soc. Clio. Oncol. (2001):421.
   Google Scholar
• MCDAID HM, MANI S, SHEN HJ et al: Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a Phase I clinical study. Clio. Cancer Res. (2002) 8(7):2035–2043.
   PubMed Web of Science ®Google Scholar
• ••Example of pharmacodynarnic data thatmay guide the development of these drugs during Phase I and II studies.
   Google Scholar
• AWADA A, JONES S, PICCART M et al: Final results of the Phase I study of the novel epothilone BMS-247550 administered weekly in patients with advanced solid tumors. Eut: J. Cancer (2002) 38 (Suppl. 7):541 (Abstract #122).
   Google Scholar
• KAYE S, OZA A, GORE M et al.: Preliminary results from a Phase II trial of EP0906 in patients with advanced refractory ovarian cancer. Eur: Cancer (2002) 38 (Suppl. 7):543 (Abstract #127).
   Google Scholar
• O'LEARY J, MUGGIA FM: Clinical oncology update: camptothecins: a review of their development and schedules of administration. Eut: Cancer(1998) 34: 1500–1508.
   Google Scholar
• GERSHENSON D: Irinotecan in epithelialovarian cancer. Oncology (2002) 16(Suppl.):29–31.
   PubMedGoogle Scholar
• NATELSON EA, GIOVANELLA BC, VERSCHRAEGEN CF et al.: Phase I clinical and pharmacological studies of 20-(5)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann. NY Acad. Sci. (1996) 803:224–230.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, JOHNSON TR, GEYER CE et al.: DX859 if (Exetecan Mesylate): a hexacyclic camptothecin analog on a daily x 5 schedule: a Phase I and pharmacokinetic study in advanced solid malignancies. J. Clio. Oncol. (2001) 19:1493–1500.
   PubMed Web of Science ®Google Scholar
• DE CESARE M, PRATESI G, PEREGO P et al.: Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res. (2001) 61:7189–7195.
   PubMed Web of Science ®Google Scholar
• ••A thorough description of the relevance ofschedule and bioavailability on the activity of topoisomerase I inhibitors.
   Google Scholar
• ABOU-ALFA G, LENZI R, MANI S et al: A Phase I/II study of DX-8951f and gemcitabine in advanced solid tumor malignancies. Ear: J. Cancer (2002) 38 (Suppl. 7):546–547 (Abstract #141).
   Google Scholar
• EMERSON DL, BENDELE RA, BROWN E et al.: Antitumor efficacy, pharmacokinetics, and biodistribution of NX211: a low clearance liposomal formulation of lurtotecan. Clin. Cancer Res (2000) 6:2903–2912.
   PubMed Web of Science ®Google Scholar
• •A prototype of developing liposomal topoisomerase I inhibitors.
   Google Scholar
• OGAWA M, MIYAMOTO H, INAGAKI J et al.: Phase I clinical trial of a new anthracycline: 4'-0-tetrahydropyranyl adriamycin. Invest. New Drugs (1983) 1:169–179.
   PubMedGoogle Scholar
• SWEATMAN TW, PARKER RF, ISRAEL M: Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD32): a preclinical study. Cancer Chemother. Pharmacol (1991) 28:1–6.
   PubMed Web of Science ®Google Scholar
• CAPONIGRO F, WILLEMSE P, SORIO R et al.: A Phase II study of MEN-10755 in patients with advanced or metastatic ovarian cancer. Eur. J. Cancer (2002) 38\(Suppl. 7):518 (Abstract #42).
   Google Scholar
• QUINTIERI L, ROSSI E, SAGGIORO D et al.: Cellular pharmacology of PNU-159682, a liver microsomal metabolite of methoxymorpholinyl doxorubicin (Nemorubicin; MMDX). Ear: I Cancer (2002) 38\(Suppl. 7):S19 (Abstract #46).
   Google Scholar
• KRAPCHO AP, LANDI JJ, HACKER MP, MCCORMACK JJ: Synthesis and antineoplastic evaluation of 5,8-bis [(aminoalkyl) amino] -1 -aza-anthracene-9,10-diones. Med. Chem. (1985) 28:1124–1126.
   Web of Science ®Google Scholar
• MUGGIA FM, BLESSING JA, HOMESLEY HD, SOROSKY J: Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a Phase II study by the Gynecologic Oncology Group. Cancer Chemother. Pharmacol (1998) 42:68–70.
   PubMed Web of Science ®Google Scholar
• BENEPAL T, PYLE L, BATE S et al: A pharmacokinetic (PK) Phase I (PI) study of ZD9331 and carboplatin in relapsed ovarian cancer with a pharmacodynamic endpoint. Ear: J. Cancer (2002) 38\(Suppl. 7):524 (Abstract #64).
   Google Scholar
• COLOMBO N, SESSA C, PEROTTI A et al.: Phase II study of 3-hour infusion ET743 in patients with refractory/relapsing ovarian cancer. Cancer Invest. (2003) (Suppl. for Chemotherapy Foundation November 2002 Symposium).
   Google Scholar
• D'INCALCI M, COLOMBO T, GIAVAZZI G et al: In human tumor xenografts the resistance to ET-743 or to cisplatin can be overcome by giving the two drugs in combination. Ear: J. Cancer (2002) 38\(Suppl. 7):534 (Abstract #99).
   PubMedGoogle Scholar
• KAVANAGH JJ, KUDELKA A, SPRIGGS DR et al.: Phase II study of TLK286 (GST P1-1 activated glutathione analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer (Abstract). (2002) Eur. Cancer38\(Suppl. 7):534–535 (Abstract #100).
   Google Scholar
• KELNER MJ, MCMORRIS TC: Irofulvenis synergistic with multiple chemotherapeutic agents. Proc. Am. Assoc. Cancer Res. (2002) 43:60 (Abstract #304).
   Google Scholar
• JACKMAN AL, VALENTI MR, BRUNTON LA et al: CB300919, a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumor xenograft. Ear: J. Cancer (2002) 38\(Suppl. 7):518 (Abstract #41).
   Google Scholar
• HOFFMAN MA, BLESSING J, MORGAN M: Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. Cynecol Oncol (2000) 81:463–465.
   Google Scholar
• •Little activity for benzothiopyranoindazoles DNA intercalators in this clinical setting.
   Google Scholar
• BANERJI U, WALTON M, JUDSON I, WORKMAN P: Combination of the heat shock protein 90 (HSP90) chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) and conventional cytotoxic agents in an ovarian cancer cell line model. Ear: J. Cancer (2002) 38\(Suppl. 7):552 (Abstract #161).
   Google Scholar
• JAYSON GC, ZWEIT J, JACKSON A et al.: Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. European Organisation for Research and Treatment of Cancer Biological Therapeutic Development Group. I Natl. Cancer Inst. (2002) 94(19):1484–1493.
   Google Scholar
• SEWELL JM, MACLEOD KG, RITCHIE A, SMYTH JF, LANGDON SP: Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa'). Br. J. Cancer(2002) 86(3):456–462.
   Google Scholar
• ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Clin. Oncol (2002) 20:110–124.
   Web of Science ®Google Scholar
• BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Clin. Oncol (2000) 19:3267–3279.
   Web of Science ®Google Scholar
• TABERNERO J, ROJO F, JIMENEZ E et al.: A Phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with advanced tumors known to overexpress the EGFR. Ear: J. Cancer (2002) 38\(Suppl. 7):569–570 (Abstract #216).
   Google Scholar
• MITA A, FOROUZESH B, HIDALGO M et al.: Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 (Erlotinib or Tarceva) in combination with docetaxel. Ear: J. Cancer (2002) 38\(Suppl. 7):553 (Abstract #166).
   Google Scholar
• GILBERT S, SCHAECHTELE C, WEINBERGER H, REISSMAN T: Functional characterization of novel epidermal growth factor receptor (EGFR) and Her2 inhibitors based on pyrrolo [2,3-dlpyrimidinone structure. Ear: J. Cancer (2002) 38\(Suppl. 7):562–563 (Abstract #199).
   Google Scholar
• BAILEY H, THOMAS J, MARNOCHA R et al.: A Phase I study of weekly BMS-214662, a novel farnesyl:protein transferase inhibitor, combined with weekly paclitaxel. Eur. J. Cancer (2002) 38\(Suppl. 7):555 (Abstract #172).
   Google Scholar
• DENKERT C, KOCH I, GURSTENBERG A et al.: Regulation and function of cyclooxygenase-2 (COX-2) in ovarian carcinoma cells. Ear: Cancer (2002) 38\(Suppl. 7):586 (Abstract #279).
   PubMedGoogle Scholar
• BARTZ R, ULLRICH S, SCHMALIX WA et al.: First dose in man Phase I study of the anti-metastatic uPA inhibitor WX-UK1.Eur. J. Cancer (2002) 38\(Suppl. 7):575–576 (Abstract #238).
   Google Scholar
• SPINELLA F, ROSANO L, DI CASTRO V et al.: Blockade of endothelin A receptor by ABT 627 suppresses tumor growth, neovascularization and potentiates cytotoxic paclitaxel activity in ovarian cancer cell in vitro and in vivo. Ear: J. Cancer (2002) 38\(Suppl. 7):S99-S100 (Abstract #330).
   Google Scholar
• DI NICOLANTONIO F, PRIN A, MILLS L et al.: The effect of MDR1 on the ex vivo activity of XR5944 (MLN944) and XR11576 (MLN576), two novel DNA targeting agents. Eur. J. Cancer (2002) 38\(Suppl. 7):S32 (Abstract #90).
   Google Scholar
• MULATERO C, GAYSON G, WAGSTAFF J et al.: Phase I safety, pharmacolkinetic and pharmacodynamic study of recombinant human anti-VEGF antibody HuMV633 in patients with advanced cancer. Ear. J. Cancer (2002) 38\(Suppl. 7):S80 (Abstract #253).
   Google Scholar
• GERARD G, FOY T, BAUDSON N et al.:Active and protective immunity induced by a protein based vaccine targeting the Her2/ neu oncogenic protein. Ear. J. Cancer (2002) 38\(Suppl. 7):S138 (Abstract #459).
   Google Scholar
• GANESANT, MADHUSUDAN S, BRAYBROOKE J et al.: A Phase II trial of etanecerpt, a tumour necrosis factor-a inhibitor in recurrent ovarian cancer. Ear. Cancer 38\(Suppl. 7):S140 (Abstract #467).
   Google Scholar
• BROWNE MK, MACKENZIE M, DOYLE PJ: A controlled trial of taurolin in established bacterial peritonitis. Surg. Gynecol. Obstet. (1978) 146:721–724.
   PubMedGoogle Scholar
• DEDRICK RL, MYERS CE, BUNGAY PM, DEVITA VT JR: Pharmacolkinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. (1978) 62(1):1–11.
   PubMedGoogle Scholar
• •Classic paper on intraperitoneal drug delivery.
   Google Scholar
• DEDRICK RL, FLESSNER MF: Pharmacolkinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J. Natl. Cancer Inst (1997) 89(7):480–487.
   PubMed Web of Science ®Google Scholar
• SUGARBAKER PH, CUNLIFFE WJ, BELLIVEAU J et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin. Oncol. (1989) 16\(Suppl. 6):83–97.
   PubMedGoogle Scholar
• MUGGIA F: Chemotherapy for refractory epithelial ovarian cancer. In: Gynecologic cancer: controversies M management. Gershenson D & McGuire W (Eds). Submitted 2003:Chapter 33.
   Google Scholar